BIOVENTUS INC. (NASDAQ: BVS) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Secu

Did you lose money on investments in Bioventus? If so, please visitBioventus Inc. Shareholder Class Action Lawsuitor contactPeter Allocco at (212) 951-2030orpallocco@bernlieb.com to discuss your rights.

NEW YORK, Jan. 25, 2023 /PRNewswire/ -- Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired: (a) Bioventus Inc. ("Bioventus") Class A common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company's initial public offering conducted on or about February 11, 2021 (the "IPO" or "Offering"); and/or (b) Bioventus securities between February 11, 2021 and November 21, 2022, both dates inclusive (the "Class Period"). The lawsuit was filed in the United States District Court for the Middle District of North Carolina and alleges violations of the Securities Act of 1933 and the Securities Exchange Act of 1934.

Bioventus is a medical device company that focuses on developing and commercializing clinical treatments to engage and enhance the body's natural healing process.